NNP
HBIO icon

Nachman Norwood & Parrott’s Harvard Bioscience HBIO Stock Holding History

Nachman Norwood & Parrott’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-313
Closed -$9K – 580
2020
Q3 		$9K Buy
+313
New +$10.5K ﹤0.01% 778

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Nachman Norwood & Parrott's HBIO Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Harvard Bioscience (HBIO) in Q4 2020, closing a stake of 313 shares — an estimated $9K sold.

Nachman Norwood & Parrott first reported a position in HBIO in Q3 2020 and held it in 1 quarter. The position peaked at $9K in Q3 2020. 81 funds tracked by Wall St. Rank hold HBIO as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Harvard Bioscience position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 313 Harvard Bioscience shares in Q4 2020, an estimated $9K.
  • Nachman Norwood & Parrott first reported a position in Harvard Bioscience in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Harvard Bioscience position peaked at $9K in Q3 2020.
  • 81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.